This overview outlines the key pathways and specialised therapeutics in biliary cancer and the emerging role of immunotherapy by highlighting the rationale and selected examples of studies in each area.

Biliary tract carcinoma (BTC) is a collective term for a group of rare gastrointestinal cancers. The intrahepatic cholangiocarcinomas (IHCC) arise from the small ducts within the liver. The more common extrahepatic cholangiocarcinomas (EHCC) include hilar and perihilar carcinomas, more distal tract tumours, and gall bladder carcinomas (GBCs). The incidence of cholangiocarcinomas is rising in the Western world, with reports of up to 2/100 000. By contrast, in Asian countries the incidence is much higher and reflects the endemic liver fluke infection as a key risk factor, as opposed to chronic inflammation from hepatitis C and primary sclerosing cholangitis in the West. GBC also has an incidence of 2/100 000, but its aetiology is primarily related to cholecystitis and cholelithiasis, as well as some chronic infections, and is much more prevalent in parts of South America. Collectively these cancers present late in the majority of patients. Long-term outcomes for resectable patients are poor (about 30% 5-year survival) and survival in the advanced setting is short with a median survival of less than 1 year.[@R1]

Historically for unresectable disease, radiation and systemic chemotherapy have been the mainstay of treatment. Drug regimens with activity include gemcitabine and oxaliplatin, gemcitabine and cisplatin, 5-fluorouracil and oxaliplatin, and single agent options including gemcitabine and capecitabine.[@R5] Although the outlook has been dismal for these diseases, the molecular genomics revolution, which has changed the paradigm of treatment in many cancers, has also led to novel approaches in biliary cancer [Table 1](#T1){ref-type="table"}. A number of clinical trials with targeted therapies have been completed in recent years ([table 1](#T1){ref-type="table"}). A key problem that has emerged, however, is the breadth of driver mutations with small patient subsets for each target and key differences across IHCC, EHCC and GBC. This combined with the rarity of the disease creates challenges with testing novel therapies.[@R4] The development of international networks for rare cancers such as the International Rare Cancers Initiative, a consortium involving the USA, Canada, Europe and Australasia,[@R6] is key to translating the identification of targets into trials to test and validate efficacy. Additionally the concept of basket trials accepting multiple anatomical sites with shared genetic changes has the potential to accelerate identification of active targeted agents.[@R7]

###### 

Incidence of molecular mutations in biliary tract cancer as determined by genomic sequencing[@R10]

  Mutation                Intrahepatic cholangiocarcinoma (%)   Extrahepatic cholangiocarcinoma (%)   Gall bladder cancer (%)
  ----------------------- ------------------------------------- ------------------------------------- -------------------------
  *ERBB2* amplification   3                                     11                                    16
  *BRAF* substitution     5                                     3                                     1
  *KRAS*                  15--22                                42--47                                11--19.2
  PI3KCA substitution     5                                     7                                     14
  FGFR1-3 fusion          11--12.5                              0                                     3
  CDKN2A/B loss           18                                    17                                    19
  *IDH1/2* substitution   15--23                                3--4                                  0
  *ARID1A* alteration     11--20                                12                                    11--13
  *MET*                   4                                     0                                     0
  *BAP1*                  9--25                                 0                                     4--13

Whole genomic tumour profiling studies have identified a wide range of mutations, amplifications and deletions, many of which have targetable options.[@R2] Important driver mutations reported in other tumours have also been documented, including the epidermal growth factor (EGF) pathway with EGF receptor (EGFR), kras and braf mutations or overexpression, as well as alteration in the mitogen-activated protein kinase and PI3K/mammalian target of rapamycin pathways, as well as TP53. Mutations in chromatin-remodelling genes *BAP1* (encoding a nuclear deubiquitinase), *ARID1A* (encoding a subunit of the SWI/SNF chromatin-remodelling complexes) and *PBRM1* (encoding a subunit of the ATP-dependent SWI/SNF chromatin-remodelling complexes) have been reported in frequencies of 10%--25%. Mutations in the metabolic pathway involving isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) are also seen. Amplifications in c-MET, FGF 19, cyclin-dependent kinase 6 and cyclin d1, as well as deletions in cyclin-dependent kinase inhibitors 2A and 2B, are all documented.[@R2]

Overall Nakamura *et al* [@R8] identified five molecular modules, with alterations varying according to anatomical location([figure 1](#F1){ref-type="fig"}). They uncovered potentially targetable genetic alterations in 38.9% of BTC cases (93/239). These potential targets included kinases (*FGFR1*, *FGFR2*, *FGFR3*, *PIK3CA*, *ALK*, *EGFR*, *ERBB2*, *BRAF* and *AKT3*), other oncogenes (*IDH1*, *IDH2*, *CCND1*, *CCND3* and *MDM2*) and tumour suppressor genes (*BRCA1* and *BRCA2*). They also identified four molecular subgroups of gene expression which clustered with clinical prognosis. Of particular interest, in one group they identified positive enrichment for genes involved in the immune system, in cytokine activity and in antiapoptotic genes. In addition there were cases where a high mutation load created abundant tumour-specific neoantigens, which were also significantly enriched in this group.
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In another analysis restricted to IHCC, profiling identified two different molecular-defined subclasses with distinctive clinical behaviour.[@R9] An 'inflammation' class (38% of patients) characterised by activation of inflammatory signalling pathways, overexpression of cytokines and *STAT3* activation, and a 'proliferation' class (62% of patients) were characterised by activation of oncogenic signalling pathways (eg, (RAS-Kirsten rat sarcoma viral oncogene homolog and MET-mesenchymal-epithelial transition factor (MET) receptor tyrosine kinase gene)), DNA amplifications at 11q13.2, deletions at 14q22.1, and mutations in *KRAS* and *BRAF*.

A significant feature of these genetic changes is the variation in targets by anatomic site. Bridgewater *et al* [@R10] have summarised these in [table 2](#T2){ref-type="table"}, showing that apart from CDK 2A/B deletions and ARID1A, there is quite a distinct variation between IHCC, EHCC and GBC. To add to this complexity, significant differences in frequency of mutations are reported in liver fluke-related cholangiocarcinomas compared with non-liver fluke in Asians and compared with Western studies.[@R2] Some of these may be related to anatomic site variations as well as aetiology.

###### 

Completed clinical trials with targeted therapies, alone or in combination with chemotherapy, in biliary tract cancers

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Therapeutic regimen\                               Authors                      Patients (n)                 End points                                          
  (target)                                                                                                                                                         
  -------------------------------------------------- ---------------------------- ---------------------------- -------------------------- ------------------------ ---------------------------------
  EGFR                                                                                                                                                             

  Cetuximab                                                                                                    RR                         PFS                      OS

  GEM and cetuximab\                                 Borbath *et al* [@R34]       44                           20.4                       6 mPFS 47                13.5
  First-line ph2                                                                                                                                                   

  GEMOX and cetuximab\                               Gruenberger *et al* [@R35]   30                           63%                        8.8                      15.2
  First-line, single-arm ph2                                                                                                                                       

  First-line versus GEMOX ph2                        Malka *et al* [@R36]         150                          23 vs 29                   6 vs 5.3                 11 vs 12.4

  First-line versus GEMOX ph2                        Chen *et al* [@R37]          122                          27 vs 15                   6.7 vs 4.1               10.6 vs 9.8

  Second-line ph2                                    Paule *et al* [@R38]         9                            33%                        EGFR low: 4 vs high: 7   EGFR low: 7 vs high: 9

  GEMCAP versus cetuximab\                           Rubovszky *et al* [@R39]     34                           17.6                       8.6                      15.7
  Anyline ph2                                                                                                                                                      

  Panitumumab                                                                                                                                                      

  GEMOX and panitumumab\                             Hezel *et al* [@R40]         31                           45%                        10.6                     20.3
  First-line ph2 KRAS WT                                                                                                                                           

  GEMOX-CAP and panitumumab\                         Jensen *et al* [@R41]        46                           33                         8.3                      10
  Anyline ph2                                                                                                                                                      

  GEM-IRINO and panitumumab\                         Sohal *et al* [@R42]         35                           39                         9.7                      12.9
  First-line ph2                                                                                                                                                   

  GEMCIS and panitumumab versus GEMCIS in KRAS WT\   Vogel *et al* [@R43]         93                           45 vs 39, pNS              6.7 vs 8.2, pNS          12.8 vs 21.4, pNS
  First-line ph2                                                                                                                                                   

  Erlotinib                                                                                                                                                        

  GEMOX and erlotinib versus GEMOX\                  Lee *et al* [@R44]           268                          30 vs 16                   5.8 vs 4.2               9.5 vs 9.5
  First-line ph3                                                                                                                                                   

  Docetaxel and erlotinib\                           Chiorean *et al* [@R45]      11                           0                                                   5.7
  Ph2                                                                                                                                                              

  Erlotinib\                                         Philip *et al* [@R46]        42                           8                          2.6                      7.5
  First-/Second-line ph2                                                                                                                                           

  HER2                                                                                                                                                             

  Lapatinib\                                         Ramanathan *et al* [@R47]    17                           0                          1.8                      5.2
  First-/Second-line ph2                                                                                                                                           

  Trastuzumab\                                       Kaseb[@R48]                  4                            50                         NR                       NR
  Second-line ph2                                                                                                                                                  

  GEMCIS and afatinib\                               Moehler *et al* [@R49]       9                            NR                         158 days                 235 days
  First-line ph1b                                                                                                                                                  

  VEGF and multitarget                                                                                                                                             

  Bevacizumab                                                                                                                                                      

  GEMOX and bevacizumab\                             Zhu *et al* [@R50]           35                           40                         7                        12.7
  First/Second ph2                                                                                                                                                 

  GEMCAP and bevacizumab\                            Iyer *et al* [@R51]          50                           72                         8.1                      11.3
  First-line ph2                                                                                                                                                   

  Sorafenib                                                                                                                                                        

  First-line ph2                                     El-Khoueiry *et al* [@R52]   31                           0                          3                        9

  Anyline ph2                                        Bengala *et al* [@R53]       46                           2                          2.3                      4.4

  GEM-sorafenib versus GEM\                          Moehler *et al* [@R54]       102                          8 vs 6                     3 vs 4.9                 8.4 vs 11.2
  First-line ph2                                                                                                                                                   

  GEMCIS and sorafenib\                              Lee *et al* [@R55]           39                           NR                         6.5                      14.4
  First-line ph2                                                                                                                                                   

  Sunitinib                                                                                                                                                        

  Second-line ph1                                    Yi *et al* [@R56]            56                           9                          1.7                      4.8

  Second-line ph2                                    Neuzillet *et al* [@R57]     53                           15\                        5.2                      9.6
                                                                                                               DCR: 85                                             

  Cediranib                                                                                                                                                        

  GEMCIS and cediranib versus GEMCIS\                Valle *et al* [@R58]         124                          44 vs 19                   8 vs 7.4                 14.1 vs 11.9
  First-line ph2/3                                                                                                                                                 

  Vandetanib\                                        Santoro *et al* [@R59]       173                          4                          105 days                 228 days
  First-line ph2                                                                                                                                                   

  FGFR                                                                                                                                                             

  BGJ398 in CC with FGFR2\                           Javle *et al* [@R60]         26                           14\                        NR                       NR\
  ≥Second-line phase 2                                                                                         DCR: 82                                             50% pts on study for \>120 days

  ODM-203                                            Ahnert *et al* [@R61]        24 (1 CC with FGFR fusion)   8                          NR                       NR (\>40 weeks for CC pt)

  MAPK pathway                                                                                                                                                     

  Selumetinib\                                       Bekaii-Saab *et al* [@R62]   28                           12                         3.7                      9.8
  First-/Second-line ph2                                                                                                                                           

  GEMCIS and selumetinib\                            Bridgewater *et al* [@R63]   12                           37.5                       6.4                      NR
  First-line ph1                                                                                                                                                   

  Trametinib                                         Ioka *et al* [@R64]          20                           5                          10.6 weeks               NR\
                                                                                                                                                                   1 pt\>9m

  Binemetinib and GEMCIS\                            Lowery *et al* [@R65]        12                           50                         6.4                      9.1
  First-line ph1                                                                                                                                                   

  MK-2206\                                           Ahn *et al* [@R66]           8                            NR                         1.7                      3.5
  ≥Second-line, ph2                                                                                                                                                

  c-MET                                                                                                                                                            

  Tivantinib + gemcitabine\                          Pant *et al* [@R67]          20                           20                         NR                       NR
  Anyline ph1                                                                                                                                                      

  Cabozanitib\                                       Goyal *et al* [@R68]         19                           0                          1.8                      5.2
  ≥Second-line ph2                                                                                                                                                 

  Multiagent/Other                                                                                                                                                 

  Bevacizumab and erlotinib\                         Lubner *et al* [@R69]        49                           12                         4.4                      9.9
  First-line ph2                                                                                                                                                   

  Sorafenib and erlotinib\                           El-Khoueiry *et al* [@R70]   34                           7                          2                        6
  First-line ph2                                                                                                                                                   

  Bortezomib\                                        Denlinger *et al* [@R71]     20                           5                          1.6                      9.5
  Second-/Third-line ph2                                                                                                                                           

  Pazopanib and trametinib\                          Shroff *et al* [@R72]        25                           5\                         4.3                      6.7
  ≥Second-line ph1b                                                                                            DCR: 75                                             

  GEMOX-CAP and panitumumab versus bev\              Jensen *et al* [@R73]        88                           46 vs 18                   6.1 vs 8.2               9.5 vs 12.3
  First-line with crossover at PD                                                                                                                                  

  IDH1                                                                                                                                                             

  AG-120                                             Burris *et al* [@R74]        20                           5\                         NR                       5 SD\>6 months
                                                                                                               DCR: 60                                             

  WNT pathway                                                                                                                                                      

  DKN-01\                                            Eads *et al* [@R75]          22 ongoing\                  33% (3 from 9 evaluable)   NR                       NR
  First-line ph1                                                                  abstract                                                                         

  Solid tumour studies                                                                                                                                             

  GDC-0919 (IDO1)                                    Nayak *et al* [@R76]         19 (1 CC)                    NR                         NR                       1 CC SD\>225 days
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CAP, capecitabine; CIS, cisplatin; DCR, disease control rate; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; GEM, gemcitabine; HER2, human epidermal growth factor receptor 2; IDH, isocitrate dehydrogenase; IRINO, irinotecan; KRAS, Kirsten rat sarcoma viral oncogene homologue; MAPK, mitogen-activated protein kinase; OS, overall survival; OX, oxaliplatin; PD, progressive disease; PFS, progression-free survival; ph, phase; RR, response rate; VEGF, vascular endothelial growth factor; WT, wild-type.

Overall the ability of genomic sequencing to appropriately segment patients into groups for which targeted treatments would be most likely to improve outcomes has been supported by the work of Javle *et al*.[@R11] They showed a similar spread of genetic changes in a large cohort of patients, but in particular in a subgroup of 321 with clinical annotation. A multivariate analysis showed that TP53 and kras mutations were indicators of inferior survival and FGFR2 of improved survival. In an analysis restricted to intrahepatic cholangiocarcinoma (IHCC), they showed that patients receiving experimental targeted therapies had a numerically better outcome than those on standard therapy (241 vs 186 weeks, p=0.07). They also showed that targeting a specific genomic association can have a major impact. They identified a number of fibroblast growth factor receptor (FGFR) aberrant expression in 54 patients. Twenty of those patients received appropriate targeted therapy and the overall survival exceeded those receiving non--FGFR-targeted therapy (25 vs 80 months, p=0.006).

Key pathways and selected studies {#s1}
=================================

Epidermal growth factor receptor {#s1a}
--------------------------------

A number of key targets have been identified, including EGFR mutation and amplification, bRAF mutation, and HER2/neu amplification. EGFR blockade has been less successful in four randomised trials, with erlotinib, cetuximab and panitumumab not showing a survival gain ([table 1](#T1){ref-type="table"}) despite promising progression-free survival.[@R12] However, a study in a more molecularly defined all RAS wild-type population may still be indicated. Identification of HER2/neu in 13% of Gb and 8% of EHCC and some retrospective data provide an impetus for more defined study.[@R13] *BRAF* mutations occur in a small number of BTC cases \[[@R2]\], and given the significant survival advantage that bRAF inhibition gives in the melanoma setting,[@R14] dual blockade with bRAF and MEK inhibitors merits evaluation in this subset. Further trials with such targets are outlined in [table 3](#T3){ref-type="table"}.

###### 

New therapies under evaluation in biliary tract cancers

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Therapeutic regimen                                                                                                            Target                                                                  Phase   ClinicalTrials.gov identifier   Status
  ------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------- ------- ------------------------------- ----------------------------------------------
  VEGF and multitarget                                                                                                                                                                                                                           

  Ramucirumab                                                                                                                    VEGFR2                                                                  2       NCT02520141                     Recruiting

  GEMCIS and ramucirumab or merestinib                                                                                           VEGFR2\                                                                 2       NCT02711553                     Recruiting
                                                                                                                                 c-MET                                                                                                           

  GEMOX and sorafenib                                                                                                            VEGFR-2/3, PDGFR-β, B-Raf, C-Raf                                        1/2     NCT00955721                     Completed (efficacy not reported)

  GEM and sorafenib                                                                                                              VEGFR-2/3, PDGFR-β, B-Raf, C-Raf                                                                                

  FOLFOX and cediranib                                                                                                           VEGFR                                                                   2       NCT01229111                     Not recruiting (no results)

  Regorafenib                                                                                                                    VEGFR1-3, c-KIT, TIE-2, PDGFR-β, C-Raf, B-Raf, p38 MAPK, FGFR1-2, Ret   2\      NCT02115542\                    Recruiting\
                                                                                                                                                                                                         2       NCT02053376                     Recruiting

  MAPK                                                                                                                                                                                                                                           

  Trametinib versus CAP/5 FU                                                                                                     MEK 1/2                                                                 2       NCT02042443                     Ongoing (not recruiting)

  Binimetinib (MEK162) and GEMCIS                                                                                                MEK 1/2                                                                 2       NCT01828034                     Active (not recruiting)

  Binimetinib and GEMOX                                                                                                          MEK 1/2                                                                 1       **NCT02105350**                 Suspended (no results)

  Binimetinib (MEK162) and capecitabine                                                                                          MEK                                                                     1       NCT02773459                     Recruiting

  Selumetinib (at different doses) and GEMCIS                                                                                    MEK 1/2                                                                 2       NCT02151084                     Recruiting

  MEK162 and capecitabine                                                                                                        MEK                                                                     1       NCT02773459                     Recruiting

  mTOR                                                                                                                                                                                                                                           

  Everolimus                                                                                                                     mTOR                                                                    2       NCT00973713                     Unknown (not verified on ClinicalTrials.gov)

  GEMCIS and everolimus                                                                                                          mTOR                                                                    1       NCT00949949                     Not recruiting (no results)

  Other                                                                                                                                                                                                                                          

  ARG 087                                                                                                                        FGFR                                                                    1/2     NCT01752920                     Recruiting

  Cabozantinib                                                                                                                   c-MET, VEGFR2                                                           2       NCT01954745                     Active, not recruiting

  AG-221                                                                                                                         IDH2 mutation                                                           1/2     NCT02273739                     Completed (not reported)

  GEMCIS and ADH1 (Exherin)                                                                                                      N-cadherin                                                              1       NCT01825603                     Recruiting

  Immunotherapy                                                                                                                                                                                                                                  

  Nivolumab                                                                                                                      PD1                                                                     2       NCT02829918                     Recruiting

  Pembrolizumab and GM-CSF                                                                                                       PD1                                                                     2       NCT02703714                     Recruiting

  Ipilimumab and nivolumab                                                                                                       CTLA4 and PD1                                                           2       NCT02923934                     Not yet recruiting

  Dendritic cell-precision T cells for neoantigen (DC-PNAT) and gemcitabine                                                      Personalised neoantigens                                                2       NCT02632019                     

  Multiagent                                                                                                                                                                                                                                     

  Multiple arms based on molecular profiling (cetuximab, trastuzumab, gefitinib, lapatinib, everolimus, sorafenib, crizotinib)   Multiple (EGFR, HER2, mTOR, VEGF/EGFR/PDGFR, ALK/ROS1)                  2       NCT02836847                     Recruiting

  Ramucirumab and pembrolizumab                                                                                                                                                                          1       NCT02443324                     Recruiting
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All cited from ClinicalTrials.gov on 21 November 2016.

5 FU, 5-fluorouracil; ALK, anaplastic lymphoma kinase; BRAF, v-Raf murine sarcoma viral oncogene homologue B; CAP, capecitabine; CIS, cisplatin; C-Raf, RAF proto-oncogene serine/threonine protein kinase; CTLA4, cytotoxic T-lymphocyte associated protein 4; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; FOLFOX, 5-fluorouracil and oxaliplatin; GEM, gemcitabine; GM-CSF, granylocyte macrophage colony stimulating factor; HER2, human epidermal growth factor receptor 2; IDH, isocitrate dehydrogenase; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; OX, oxaliplatin; PDGFR, platelet-derived growth factor receptor; PD1, programmed cell death protein 1; ROS1, c-ros oncogene 1; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.

Fibroblast growth factor receptor {#s1b}
---------------------------------

FGF mutations and fusions predominate in IHCCs in about 16% of cases.[@R2] There are now FGFR-targeted therapies undergoing clinical evaluation. These include multitargeted tyrosine kinase inhibitor (TKIs) that also inhibit FGFR (such as ponatinib, nintedanib, dovitinib and brivanib), as well as specific FGFR-directed small molecule TKI (eg, BGJ398), FGFR antibodies and FGFR trap molecules.[@R2] A recent phase II interim report was presented of BGJ398. Fifty patients with BTC having *FGFR* genetic alterations were enrolled, the majority being intrahepatic cholangio carcinoma (IHCC). The overall response rate was 15% and the disease control rate was 95% with progression-free survival of 6 months, supporting further development of FGFR-directed therapy for *FGFR* mutated cholangiocarcinoma.[@R15]

IDH1 and IDH2 mutations in BTC {#s1c}
------------------------------

Mutations in *IDH1* and *IDH2* have been identified in cholangiocarcinoma. In IHCC, an estimated 20% have *IDH1,* whereas 5% have *IDH2* mutations.[@R2] These mutations are not seen in EHCC or GBC.[@R2] The mutated IDH1 and IDH2 proteins have a gain-of-function activity, catalysing the reduction of α-ketoglutarate to 2-hydroxyglutarate (2 HG) by NADPH. Cancer-associated *IDH* mutations block normal cellular differentiation and promote tumorigenesis via the abnormal production of the oncometabolite 2 HG,[@R16] although their prognostic significance is controversial.[@R2] Preliminary results from phase I clinical trials with IDH inhibitors in patients with advanced haematological malignancies have demonstrated an objective response rate ranging from 31% to 40% with durable responses (\>1 year) observed.[@R16] Furthermore, the IDH inhibitors have demonstrated early signals of activity in solid tumours with IDH mutations, including cholangiocarcinomas and low-grade gliomas. Recently, Burris *et al* [@R17] reported the findings of a dose escalation study of AG-120 in various cancer types having these mutations. Of the 20 cholangiocarcinoma patients enrolled, response or stability was noted in 12 patients, with disease stability seen beyond 6 months.

Mutations in chromatin remodelling genes {#s1d}
----------------------------------------

Chromatin remodelling allows genomic DNA to access regulatory transcriptional proteins and thereby controls gene expression. Inactivating genetic alterations in *ARID*, *BAP1*, *PBRM* and *MLL* that are responsible for chromatin remodelling have been implicated in the development of BTC. Jiao *et al* [@R18] observed that mutations in at least one of these genes occurred in almost half of the BTCs sequenced in their study. The prognostic role of mutations in chromatin remodelling genes is currently unknown, although *BAP1* mutations were associated with aggressive disease resulting in bony metastases.[@R2] It is hypothesised that histone deacetylase inhibitors such as vorinostat and panobinostat may offer therapeutic value in this setting.[@R2]

Vascular endothelial growth factor (VEGF) {#s1e}
-----------------------------------------

VEGF expression is increased in many biliary tract cancers, and its expression is associated with metastasis and poor survival. In one retrospective study of 239 cholangiocarcinomas, VEGF was overexpressed in 53.8% and 59.2% of intrahepatic and EHCC, respectively.[@R19] On this basis, the multitargeted kinase inhibitors of VEGF receptors, such as sorafenib and sunitinib, have been studied without encouraging results.[@R12] Similarly, a recent randomised study with cediranib[@R21] and a study with the multitargeted kinase vandetanib[@R22] have also failed to demonstrate a survival advantage, also outlined in [table 1](#T1){ref-type="table"}. The major stumbling block remains the absence of a reliable biomarker of efficacy for VEGF inhibitors.

DNA repair mutations in BTC {#s1f}
---------------------------

DNA repair mechanisms are essential for maintaining genomic stability and defects in these occur in BTC. Gene mutations leading to defective DNA mismatch repair (MMR) are commonly seen in several solid tumours like colorectal cancer, endometrial and gastric cancer.*[@R2]* Report on 321 BTCs who underwent mutational profiling, and DNA repair mutations (*MSH6*, *BRCA1*, *BRCA2*, *ATM*, *MLH1* or *MSH*2 genes) occurred in 13% IHCCA, 26% in EHCCA and 6% of GBC cases.[@R11] The subset of cancers with MMR system defects is very sensitive to programmed cell death protein 1 (PD-1) blockade using checkpoint inhibitor agents like pembrolizumab.[@R23] BTC patients with mutations in the DNA repair pathways can represent a subset where specific DNA repair inhibitors in addition to immunotherapy may be effective.

Immunotherapy {#s1g}
-------------

Biliary tract cancers represent a potentially attractive target for immune-based therapies given the background association with chronic inflammation[@R24] and conditions such as cholecystitis, sclerosing cholangitis and primary biliary cirrhosis.[@R25]

Recognition that an activated tumour microenvironment exists in biliary cancers encourages a focus on adoptive therapy. There are identified tumour antigens, and the presence of both CD 4+, CD 8+ and Fox3+ T lymphocytes[@R26] and macrophages suggests both that response to antigen may occur in selected patients and that relevant cells can be isolated and stimulated ex vivo. The correlation of activated immune cell infiltration and better outcomes supports a focus on this area.[@R27]

Approaches to modulating the immune system include:vaccination with putative tumour antigens either as peptides or loaded within dendritic cells to enhance recognition;adoptive immunotherapy where patients\' own T cells are expanded ex vivo and reinfused;reversing tumour cell-induced immune suppression.

Vaccination against tumour-associated antigens is attractive as a number of proteins that are overexpressed have been identified.[@R28] At least two tumour-related antigens have been identified with moderate to high expression in biliary cancers -- Wilms tumour 1 (WT1) and mucin-1 (MUC-1).[@R29] Trials of both a dendritic-based cell vaccine against both antigens[@R30] as well as a randomised trial of chemotherapy and a WT1 vaccine in patients with advanced biliary cancer have been described,[@R31] as has a trial of combining a dendritic cell pulsed vaccine plus ex vivo activated T cells in the postoperative setting.[@R32] The future of antigen-based therapy may require more refinement as both the distribution of the antigens varies, as does the degree of immune response to them. An approach that identifies those most likely to be responded to in each patient is one such method.[@R27]

Recently the unpacking of the mechanisms behind tumour-induced immunosuppression has created optimism throughout the cancer community. Data on melanoma, non-small cell lung cancer and renal cancer have all sparked the search for identification of suitable patients for PD-1, PDL-1 and CTLA4 therapies, which can reverse immune suppression. The study by Nakamura *et al* [@R8] found that the worst prognosis for BTC patients was in those with relatively hypermutated tumours and elevated expression of checkpoint molecules such as CTLA-4 and PDL-1. In total, 45.2% of cases showed an increase in the expression of immune checkpoint molecules. In Keynote-026, a trial of pembrolizumab in advanced biliary tract patients, Bang *et al* [@R33] reported interim results, that of 89 screened patients 37 (42%) had PD-L1-positive tumours, of those 24 were studied. Eight patients (34%) had response or stable disease lasting 40+ weeks. The variation in immune predictors by anatomic site suggests a need for appropriate selection to trials.[@R25] In addition there is potential for augmenting tumour immunity with both chemotherapy and radiation. A number of immunotherapy studies are currently recruiting, some of which are outlined in [table 3](#T3){ref-type="table"}. Ultimately combination studies that use all three approaches to immunotherapy in the context of standard therapy are the most likely to provide sustained benefit.

Conclusions {#s2}
===========

Biliary tract cancers represent a key model of a rare cancer with complex genetic associations. Increasingly it is clear that this anatomic site is a collection of quite disparate genomically distinct neoplasms. Although easily viewed as an intractable problem with a multiplicity of small subgroups, a new approach agnostic to tissue of origin may represent a significant way forward. Instead of dedicated studies in each of intrahepatic, extrahepatic and gall bladder cancer, it may be possible to focus on the new basket trial designs, where a study of a particular targeted therapy directed at a specific mutation is identified and different histological subtypes with the right target are enrolled. If activity is shown, then an expansion study in that indication would follow. When patients are treated in a defined/personalised approach with the right target chosen, informed by their genomic landscape, we can expect to finally make some movement in dealing with this difficult group of diseases.
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